Anuh Pharma Q1 FY27 PAT jumps 38% to ₹11.42 cr

Newspaper notice and investor access

Anuh Pharma Limited published newspaper notices announcing the availability of its unaudited financial results for the quarter ended 30 June 2026. The notices appeared on 9 August 2026 in the Financial Express (English) and Mumbai Lakshdeep (Marathi). The publication also carried a QR code that directs investors to the full financial statements hosted on the company’s website. Such notices are typically used to widen access for shareholders who may not track exchange filings regularly. The update comes as investors monitor the July to August results season for the June quarter.

What the company reported for Q1 FY27

For Q1 FY27 (quarter ended 30 June 2026), Anuh Pharma reported a sharp improvement in profitability on a modest rise in revenue. Standalone revenue from operations increased 3.9% year-on-year to ₹193.81 crore. Over the same period, standalone net profit after tax rose 37.6% to ₹11.42 crore. The company attributed the improvement primarily to EBITDA margin expansion, indicating better operating leverage versus the prior-year quarter. The numbers were reported as unaudited standalone results.

Margin expansion drove the profit rise

A key feature of the quarter was the widening of EBITDA margin to 9.47% from 7.34% in Q1 FY26. EBITDA increased 34.2% year-on-year to ₹18.35 crore, compared with ₹13.68 crore in the year-ago quarter. The margin improvement meant earnings grew much faster than revenue, even though the topline increase was in low single digits. Earnings per share (basic) for the quarter rose to ₹1.14 from ₹0.83, a 37.3% increase. The results suggest that operating performance, rather than a step-change in sales, was the primary contributor to the quarter’s profit growth.

Key Q1 numbers at a glance

The table below summarises the figures provided for Q1 FY27 versus Q1 FY26.

Sequential movement mentioned in the snapshot

The market snapshot included in the provided data also pointed to a sequential decline in revenue. It said revenue fell about 4.02% from ₹202.12 crore in Q4 FY26 to about ₹194 crore in Q1 FY27. This sequential comparison is consistent with the quarter’s reported revenue of ₹193.81 crore when rounded. The same snapshot described year-on-year revenue growth at roughly 4.30% (using rounded figures of ₹194 crore versus ₹186 crore). While the quarter showed strong profit growth year-on-year, the sequential revenue comparison highlights that the topline did not increase quarter-on-quarter.

Promoter reclassification applications withdrawn

Alongside the quarterly update, the provided text notes that promoters withdrew share reclassification applications. The material did not specify the reasons, timing, or the exact nature of the reclassification sought. With only this information available, the key takeaway is that the process was initiated earlier but has now been withdrawn. Investors typically track such changes because they can affect shareholding categorisation and related disclosures.

AGM scheduled on August 12, 2026

Anuh Pharma has scheduled its 66th Annual General Meeting for 12 August 2026. The AGM is planned via video conferencing, as stated in the provided information. Agenda items include adopting the financial statements for FY26 and declaring a final dividend. The dividend amount was not specified in the text. AGM outcomes can be important for shareholders as they formalise financial approvals and corporate actions.

Valuation and trading references cited

The dataset included a snapshot that placed Anuh Pharma’s shares at a current market price (CMP) of ₹79, with a market capitalisation of ₹791 crore and a price-to-earnings multiple of 19.2. It also referenced a “12-month target” range of ₹80 to ₹91 attributed to “Uniresearch Estimate.” Separately, another line in the material stated that the current price of Anuh Pharma Ltd is ₹76.21, and also listed “BSE: 506260 153.40 -0.20,” without context on timing or what the latter quote represented. Given these differing price points in the provided text, readers should treat them as source-reported snapshots rather than a single definitive real-time price.

FY26 context provided in earlier update

The material also referenced FY26 operating and financial context dated 28 May 2026. It stated FY26 revenue grew 15.66% to ₹776 crore, with EBITDA of ₹67.84 crore (up 6.52%). It also reported total production of 1,733 MT (up 24.99%) and export sales contributing 46% of revenue, with presence across Asia, Africa, and Europe. EBITDA margin for FY26 was cited at 8.56%, while net profit margin was 5.32%. FY26 profit after tax was reported at ₹41.05 crore, down 13.32% year-on-year, with EPS at ₹4.10.

Market impact and why the quarter matters

From an investor perspective, the Q1 FY27 numbers point to a meaningful improvement in profitability metrics, particularly the jump in EBITDA and PAT against modest revenue growth. The margin increase to 9.47% from 7.34% is the central operating change highlighted in the data. For market participants, such a move can affect how the quarter is interpreted, because it suggests either cost control, product mix changes, or other operating efficiencies, although no further drivers were provided. The publication of results via newspapers, including a QR code to the financial statements, also signals an effort to keep disclosures accessible to a wider shareholder base.

Conclusion

Anuh Pharma’s unaudited standalone Q1 FY27 results show revenue of ₹193.81 crore and net profit of ₹11.42 crore, with EBITDA margin expanding to 9.47%. The company also issued newspaper notices on 9 August 2026 to highlight the availability of the results and linked investors to the full statements via a QR code. Separately, promoters withdrew share reclassification applications, and the company has scheduled its 66th AGM for 12 August 2026 to adopt FY26 financial statements and declare a final dividend.